A little more than a year after an unexpected complete response letter, ViiV Healthcare has obtained US Food and Drug Administration approval of Cabenuva, a long-acting, injectable regimen for HIV-positive patients that will enable them to go from daily to monthly dosing. The GlaxoSmithKline plc affiliate announced wholesale acquisition cost (WAC) pricing of $3,960 per month for the two-drug regimen on 22 January, following a first-month price of $5,940 for a higher initiation dose.
ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
More from New Products
More from Scrip
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
Recent moves in the industry include C-suite changes at 23andMe, Biomea Fusion & Alector, plus Bicycle Therapeutics acquires chief medical officer from ImmunoGen.